The initiation of coverage by a reputable analyst with a Buy rating and a significant price target suggests a positive outlook for Contineum Therapeutics. This endorsement is likely to generate investor interest and could lead to a short-term increase in the stock price, given the credibility of Stifel and the analyst's positive assessment.